Join Growin Stock Community!

Citius oncology, inc.CTOR.US Overview

US StockHealthcare
(No presentation for CTOR)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

CTOR AI Insights

CTOR Overall Performance

CTOR AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

CTOR Recent Performance

-3.57%

Citius oncology, inc.

0.05%

Avg of Sector

-0.31%

S&P500

CTOR PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

CTOR Key Information

CTOR Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

CTOR Profile

Citius Oncology, Inc. focuses on the development of novel targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma. The company is headquartered in New York, New York. Citius Oncology, Inc. operates as a subsidiary of Citius Pharmaceuticals, Inc.

Price of CTOR

CTOR FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

CTOR Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.27
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
25.07
PB Ratio
1.69
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
79.99%
Net Margin
-599.28%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.27
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
25.07
PB Ratio
1.69
Price-to-FCF
-
Gross Margin
79.99%
Net Margin
-599.28%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is CTOR's latest earnings report released?

    The most recent financial report for Citius oncology, inc. (CTOR) covers the period of 2026Q1 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating CTOR's short-term business performance and financial health. For the latest updates on CTOR's earnings releases, visit this page regularly.

  • What is the operating profit of CTOR?

    According to the latest financial report, Citius oncology, inc. (CTOR) reported an Operating Profit of -5.25M with an Operating Margin of -133.17% this period, representing a growth of 17.87% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is CTOR's revenue growth?

    In the latest financial report, Citius oncology, inc. (CTOR) announced revenue of 3.94M, with a Year-Over-Year growth rate of 0%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does CTOR have?

    At the end of the period, Citius oncology, inc. (CTOR) held Total Cash and Cash Equivalents of 7.3M, accounting for 0.07 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does CTOR go with three margins increasing?

    In the latest report, Citius oncology, inc. (CTOR) did not achieve the “three margins increasing” benchmark, with a gross margin of 80%%, operating margin of -133.17%%, and net margin of -140.3%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess CTOR's profit trajectory and future growth potential.

  • Is CTOR's EPS continuing to grow?

    According to the past four quarterly reports, Citius oncology, inc. (CTOR)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.06. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.